Seelos Therapeutics Added to the Russell 2000®, Russell 3000® and Russell Microcap® IndexesPRNewsWire • 06/28/21
Seelos Therapeutics Announces its Inclusion in the First U.S. Listed Exchange Traded Fund (ETF) Focused on PsychedelicsPRNewsWire • 06/01/21
Seelos's Amyotrophic Lateral Sclerosis Candidate, SLS-005 An Orphan Drug In EuropeBenzinga • 05/27/21
Seelos Therapeutics Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis (ALS)PRNewsWire • 05/27/21
Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesPRNewsWire • 05/24/21
Seelos Therapeutics to Participate in The Benchmark Company Healthcare ConferencePRNewsWire • 05/21/21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common StockPRNewsWire • 05/20/21
Do Options Traders Know Something About Seelos (SEEL) Stock We Don't?Zacks Investment Research • 05/19/21
Seelos Therapeutics' SLS-002 Shows Clinically Meaningful Efficacy As Anti-Depressive, Anti-Suicidal Therapeutic After Single DoseBenzinga • 05/17/21
Seelos Therapeutics Announces Positive Topline Data from the Open-Label Study of SLS-002 (Intranasal Racemic Ketamine), Demonstrating a Significant Treatment Effect and a Well Tolerated Safety Profile for Acute Suicidal Ideation and Behavior in Patients wPRNewsWire • 05/17/21
Seelos Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare ConferencePRNewsWire • 05/10/21
Seelos Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis (ALS)PRNewsWire • 04/20/21
Seelos Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare ConferencePRNewsWire • 04/19/21
Seelos Therapeutics to Participate in the B. Riley Securities' Neuroscience ConferencePRNewsWire • 04/15/21